TELA Bio Q2 Revenue Falls 4%, Going Concern Warning Issued as Covenant Breach Looms

summarizeSummary

TELA Bio reported a 4% revenue decline and a wider net loss for Q2 2026, and warned it will likely breach its debt covenant, raising substantial doubt about its ability to continue as a going concern.

check_boxKey Events · Earnings and Guidance · TELA

• Going Concern Warning

  Management concluded substantial doubt exists about the company's ability to continue as a going concern, as it is probable it will breach the minimum revenue covenant under its $60M Perceptive Credit Agreement within the next twelve months.

• Revenue Decline

  Q2 2026 revenue fell 4% year-over-year to $19.3 million, driven by a 23% drop in OviTex PRS unit sales, partially offset by a 12% increase in OviTex units.

• Widening Losses

  Net loss increased 13% to $11.3 million, with interest expense nearly doubling to $2.1 million due to the higher-cost Perceptive debt.

• Cash Burn Accelerates

  Cash used in operations was $20.6 million in H1 2026, reducing cash reserves to $30.4 million as of June 30, 2026, from $50.8 million at year-end 2025.

auto_awesomeAnalysis · TELA · Industrial Applications And Services

TELA Bio's Q2 2026 results confirm a deepening crisis. Revenue dropped 4% to $19.3 million, driven by a sharp decline in OviTex PRS sales, while the net loss widened to $11.3 million. More critically, management disclosed that it is probable the company will breach its minimum revenue covenant under the Perceptive Credit Agreement within the next twelve months, raising substantial doubt about its ability to continue as a going concern. With only $30.4 million in cash and a $60 million debt load, the company is now scrambling to negotiate a waiver or amendment with its lender. This filing comes just days after the new CEO withdrew full-year guidance, painting a dire picture of a company fighting for survival.